Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Capricor Therapeutics, Inc. on June 3, 2022. The meeting took place at the company's principal executive offices in San Diego, California.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders representing 14,825,152 shares (of 24,324,156 entitled to vote) participated in the meeting. The results for the three proposals were as follows:
- Election of Directors: All seven nominees were elected to the Board of Directors. Notably, while all were elected, a significant number of shares were withheld for several directors, ranging from approximately 1.5 million to 2.5 million shares withheld per nominee.
- Ratification of Auditors: The appointment of Rose, Snyder & Jacobs LLP as the independent registered accounting firm was ratified with 13,494,227 votes FOR, 865,366 AGAINST, and 465,559 ABSTAIN.
- Executive Compensation (Say-on-Pay): The advisory vote on named executive officer compensation was approved, though with a split vote. Results were 3,703,188 FOR, 3,038,000 AGAINST, and 109,310 ABSTAIN.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. It strictly details the procedural outcomes of the annual stockholder meeting.
Key Facts for Investor Verification
- Verify the specific reasons for the high number of "Withheld" votes for the director elections, as this may indicate shareholder dissatisfaction with specific board members.
- Note the significant opposition to the executive compensation proposal (approximately 45% of votes cast were AGAINST), which may signal concerns regarding pay practices.
- Confirm the tenure of the newly elected directors, who will serve until the 2023 annual meeting.
- Review the definitive proxy statement filed on April 12, 2022, for detailed biographies of the directors and the rationale behind the compensation plan.